Journal article icon

Journal article

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial

Abstract:

Background: There has been a significant change in trials methodology for solid tumours, in response to our greater understanding of cancer biology. FOCUS4 is a phase II/III trial programme testing targeted agents in patients with advanced colorectal cancer (CRC) in molecularly stratified cohorts. Here we present the first results testing the hypothesis that combined Her 1,2,3 signal inhibition, using the tyrosine kinase inhibitor AZD8931, will control growth of ‘all wildtype’ tumours.

... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/S2468-1253(17)30394-1

Authors


Expand authors...
More from this funder
Grant:
*Grant Number Example*
Expand funders...
Publisher:
Elsevier Publisher's website
Journal:
Lancet Gastroenterology and Hepatology Journal website
Volume:
3
Issue:
3
Pages:
162-171
Publication date:
2017-01-01
Acceptance date:
2017-11-09
DOI:
EISSN:
2468-1253
Source identifiers:
744823
Pubs id:
pubs:744823
UUID:
uuid:02cda4d2-7789-4372-ad71-dd4145a107be
Local pid:
pubs:744823
Deposit date:
2017-11-10

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP